Latest News for: pcsk9

Edit

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic ...

Times Argus 20 Jan 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan 20, 2026-- ....
Edit

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

Pharmiweb 20 Jan 2026
STX-1150 is a novel liver-targeted therapy designed to epigenetically silence PCSK9 and durably reduce low-density lipoprotein cholesterol (LDL-C) without permanent DNA changes ... About PCSK9 and its Role in Elevated LDL-C.
Edit

Dr. Christie M. Ballantyne & Dr. Alexander Tal - Oral PCSK9 Therapy And The Future ...

Rumble 10 Jan 2026
Click the Rumble article link to see the video ....
Edit

Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction

PR Newswire 17 Dec 2025
SHANGHAI and SANTA BARBARA, Calif., Dec ... RN5681 is a GalNAc-conjugated, dual-targeting siRNA designed to simultaneously silence both PCSK9 and LPA, two genetically validated and complementary drivers of atherosclerotic cardiovascular disease ... Dr ... 21% ... .
  • 1

Article Search

tools
×
×
×
×